NB Therapeutics has two technology platforms: iontophoresis and nitric oxide gas. Through these two technology platforms, NB Therapeutics seeks to address the inherent challenges of drug delivery for diseases of the skin and nails:
- Orally administered drugs may be associated with systemic adverse events at the high doses required to achieve sufficient concentrations for a therapeutic effect in the skin or nails.
- Topical drugs may have limited efficacy because the active ingredient does not cross the skin barrier or penetrate the nail effectively.
- Some agents with beneficial therapeutic actions are not stable as topical preparations.